HRP20200031T1 - Uporaba cerebrolizina - Google Patents
Uporaba cerebrolizina Download PDFInfo
- Publication number
- HRP20200031T1 HRP20200031T1 HRP20200031TT HRP20200031T HRP20200031T1 HR P20200031 T1 HRP20200031 T1 HR P20200031T1 HR P20200031T T HRP20200031T T HR P20200031TT HR P20200031 T HRP20200031 T HR P20200031T HR P20200031 T1 HRP20200031 T1 HR P20200031T1
- Authority
- HR
- Croatia
- Prior art keywords
- cerebrolysin
- use according
- treated
- infusion
- cadasil
- Prior art date
Links
- 208000010482 CADASIL Diseases 0.000 claims 9
- 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims 9
- 208000033935 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy Diseases 0.000 claims 9
- 208000016886 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims 9
- 238000001802 infusion Methods 0.000 claims 6
- 239000012141 concentrate Substances 0.000 claims 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 101150103623 NOTCH3 gene Proteins 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
Claims (12)
1. Cerebrolizin, naznačen time, da se upotrebljava za smanjivanje smrtnosti kod CADASIL pacijenata.
2. Cerebrolizin za uporabu prema patentnom zahtjevu 1, naznačen time, da CADASIL pacijent ima mutaciju u genu Notch3.
3. Cerebrolizin za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time, da se CADASIL pacijent liječi sa cerebrolizinskim pripravkom koji sadrži od 50 do 1000 mg, poželjno od 100 do 500 mg, prvenstveno od 150 do 250 mg koncentrata cerebrolizina po ml u vodenoj otopini.
4. Cerebrolizin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da se CADASIL pacijent liječi s dozom koja se nalazi u rasponu od 0,1 do 100 ml, poželjno od 1 do 50 ml cerebrolizina, što odgovara za 21,5 do 21.520 mg koncentrata cerebrolizina.
5. Cerebrolizin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da se CADASIL pacijent liječi s intramuskularno primijenjenoj dozi od 0,1 do 10 ml, poželjno od 0,5 do 5 ml, što odgovara za 21,5 mg do 2152 mg koncentrata cerebrolizina.
6. Cerebrolizin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da se CADASIL pacijent liječi s intravenozno primijenjenoj dozi od 0,1 do 100 ml, poželjno od 1 do 50 ml, što odgovara za 215,2 do 21.520 mg koncentrata cerebrolizina.
7. Cerebrolizin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da se CADASIL pacijent liječi kontinuiranom infuzijom cerebrolizina.
8. Cerebrolizin za uporabu prema patentnom zahtjevu 7, naznačen time, da se infuzija provodi u trajanju infuzije od 5 minuta do 4 sata, poželjno od 10 min do 2 sata, prvenstveno od 15 do 60 minuta; i/ili gdje se infuzija provodi u jednom danu do 100 dana, poželjno za 5 do 50 dana, prvenstveno za 10 do 30 dana.
9. Cerebrolizin za uporabu prema patentnom zahtjevu 8, naznačen time, da se infuzija provodi jednom u danu.
10. Cerebrolizin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da se infuzija provodi pomoću razrjeđivanja cerebrolizina s 0,9%-tnom otopinom natrijevog klorida, Ringerovom otopinom, ili 5%-tnom glukozom.
11. Cerebrolizin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da se CADASIL pacijent liječi s cerebrolizinskim pripravkom koji sadrži natrijev hidroksid.
12. Cerebrolizin za uporabu prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da se CADASIL pacijent liječi u ciklusima liječenja koji se ponavljaju nakon vremenskog perioda bez liječenja od 1 do 6 mjeseci, poželjno od 1 do 3 mjeseca, prvenstveno od 2 do 3 mjeseca.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17188180.8A EP3449931B1 (en) | 2017-08-28 | 2017-08-28 | Use of cerebrolysin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200031T1 true HRP20200031T1 (hr) | 2020-03-20 |
Family
ID=59745228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200031TT HRP20200031T1 (hr) | 2017-08-28 | 2020-01-09 | Uporaba cerebrolizina |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12589118B2 (hr) |
| EP (2) | EP3449931B1 (hr) |
| JP (1) | JP7281450B2 (hr) |
| KR (1) | KR102676274B1 (hr) |
| CN (1) | CN111050780B (hr) |
| AU (1) | AU2018326339A1 (hr) |
| CA (1) | CA3073991A1 (hr) |
| EA (1) | EA202090108A1 (hr) |
| ES (2) | ES2767070T3 (hr) |
| HR (1) | HRP20200031T1 (hr) |
| MX (1) | MX2020002267A (hr) |
| PH (1) | PH12020500376A1 (hr) |
| PL (2) | PL3449931T3 (hr) |
| UA (1) | UA129400C2 (hr) |
| WO (1) | WO2019042983A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220168325A1 (en) * | 2019-03-25 | 2022-06-02 | The University Of Vermont | Methods to promote cerebral blood flow in the brain |
| ES2964145T3 (es) | 2020-07-13 | 2024-04-04 | Ever Neuro Pharma Gmbh | Método para producir un hidrolizado de proteína de cerebro de mamífero |
| KR20240159455A (ko) * | 2021-06-02 | 2024-11-05 | 리제너론 파마슈티칼스 인코포레이티드 | 신경성 유전자좌 노치 상동체 단백질 3(notch3) 제제를 이용한 뇌혈관 질환의 치료 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69126563T2 (de) | 1990-04-12 | 1998-02-05 | Ebewe Arzneimittel | Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia |
| EP1857463A1 (en) * | 2006-05-03 | 2007-11-21 | Ebewe Pharma Ges.m.b.H. Nfg. KG | Peptide having neuroprotective effects |
| CA2734646C (en) | 2008-08-20 | 2016-06-28 | James W. Mcginity | Hot-melt extrusion of modified release multi-particulates |
-
2017
- 2017-08-28 PL PL17188180T patent/PL3449931T3/pl unknown
- 2017-08-28 EP EP17188180.8A patent/EP3449931B1/en active Active
- 2017-08-28 ES ES17188180T patent/ES2767070T3/es active Active
-
2018
- 2018-08-28 US US16/642,307 patent/US12589118B2/en active Active
- 2018-08-28 UA UAA202001881A patent/UA129400C2/uk unknown
- 2018-08-28 CA CA3073991A patent/CA3073991A1/en active Pending
- 2018-08-28 EP EP18759322.3A patent/EP3675879B1/en active Active
- 2018-08-28 ES ES18759322T patent/ES2901508T3/es active Active
- 2018-08-28 JP JP2020512835A patent/JP7281450B2/ja active Active
- 2018-08-28 CN CN201880055542.5A patent/CN111050780B/zh active Active
- 2018-08-28 PL PL18759322T patent/PL3675879T3/pl unknown
- 2018-08-28 KR KR1020207007069A patent/KR102676274B1/ko active Active
- 2018-08-28 AU AU2018326339A patent/AU2018326339A1/en not_active Abandoned
- 2018-08-28 EA EA202090108A patent/EA202090108A1/ru unknown
- 2018-08-28 MX MX2020002267A patent/MX2020002267A/es unknown
- 2018-08-28 WO PCT/EP2018/073106 patent/WO2019042983A1/en not_active Ceased
-
2020
- 2020-01-09 HR HRP20200031TT patent/HRP20200031T1/hr unknown
- 2020-02-26 PH PH12020500376A patent/PH12020500376A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3449931A1 (en) | 2019-03-06 |
| EP3675879B1 (en) | 2021-09-15 |
| PL3675879T3 (pl) | 2022-02-14 |
| CN111050780A (zh) | 2020-04-21 |
| WO2019042983A1 (en) | 2019-03-07 |
| CN111050780B (zh) | 2023-11-03 |
| KR20200045503A (ko) | 2020-05-04 |
| PH12020500376A1 (en) | 2020-12-07 |
| EA202090108A1 (ru) | 2020-03-31 |
| PL3449931T3 (pl) | 2020-06-01 |
| CA3073991A1 (en) | 2019-03-07 |
| MX2020002267A (es) | 2020-10-22 |
| EP3449931B1 (en) | 2019-10-16 |
| US20200376040A1 (en) | 2020-12-03 |
| ES2767070T3 (es) | 2020-06-16 |
| JP2020531568A (ja) | 2020-11-05 |
| JP7281450B2 (ja) | 2023-05-25 |
| US12589118B2 (en) | 2026-03-31 |
| ES2901508T3 (es) | 2022-03-22 |
| EP3675879A1 (en) | 2020-07-08 |
| AU2018326339A1 (en) | 2020-03-05 |
| KR102676274B1 (ko) | 2024-06-18 |
| UA129400C2 (uk) | 2025-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4233861A3 (en) | Compositions for treatment of essential tremor | |
| MX2022004012A (es) | Solucion de bloqueo de cateter y terapia de bloqueo de cateter. | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| NZ800220A (en) | Methods of treating heart failure by administering omecamtiv mecarbil | |
| HRP20191285T1 (hr) | Predlijekovi karbidopa i l-dopa te njihova uporaba za liječenje parkinsonove bolesti | |
| EP4342532A3 (en) | Antiplatelet drugs and uses thereof | |
| NZ721500A (en) | Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury | |
| JP2015518818A5 (hr) | ||
| MX2023005014A (es) | Metodos de tratamiento de enfermedades inflamatorias cronicas. | |
| ZA201704327B (en) | Methods and compositions for treating brain diseases | |
| JP2016535044A5 (hr) | ||
| HRP20220470T4 (hr) | Uporaba landiolol hidroklorida u dugotrajnom liječenju tahiaritmija | |
| NZ754706A (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
| MY170991A (en) | Dosing regimens of celgosivir for the treatment of dengue | |
| MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| JP2013520447A5 (hr) | ||
| JP2020531568A5 (hr) | ||
| ZA202203357B (en) | Rifabutin treatment methods, uses, and compositions | |
| RU2020127436A (ru) | Композиция для лечения пациента, страдающего язвенным колитом, и применение композиции в качестве лекарственного средства | |
| SA518391400B1 (ar) | تركيب للمعالجة من العقم في كائن أنثوي | |
| MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. | |
| EA201491841A1 (ru) | Состав эсмолола для парентерального введения | |
| RU2010107158A (ru) | Способ лечения экомодифицированного атопического дерматита у детей, проживающих в условиях воздействия техногенных химических факторов | |
| RU2013142835A (ru) | Способ лечения ишемического инсульта |